# JinHe Ziben

> JinHe Ziben is a VC fund backing Medical, Biotechnology and Genetics. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 11
- Last investment: May 2026
- Lead investor: 27%
- Last updated: Aug 2026

JinHe Ziben is an investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 18% |
| Biotechnology | 2 | 18% |
| Genetics | 1 | 9% |
| Health Care | 1 | 9% |
| Manufacturing | 1 | 9% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 18% |
| Funding Round | 2 | 18% |
| Series B | 1 | 9% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 4 | 36% |
| United States | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Degron Therapeutics | Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment. | $40M | Series A | May 14, 2026 |  |
| Novamab | Novamab focuses on the research and development of new nanobodies. The core members of the team have 15 years of experience in nanobody research and development, and are domestic nanobody "pioneers". At present, they have established an inhaled macromolecular drug research and development platform, an albumin nanobody long-acting platformand a nanobody double-antibody platform, etc., to give full play to nanobody The advantages of antibodies, the development of innovative nanobody drugs such as sprays and eye drops, to solve the pain points of clinical major chronic diseases in terms of administration methods, administration cycles, etc. | $43.9M | Series B | Apr 24, 2026 |  |
| Treat Gut | Treat Gut provides a comprehensive solution for precise bacterial transplantation treatment. | $13.9M |  | Jun 27, 2025 |  |
| Dishi Medical | Dishi Medical is a company that manufactures Ophthalmic Medical Devices and other micro-assisted robots supported by biotechnology. | $13.7M | Series A | Apr 27, 2025 |  |
| GeneMind Biosciences | GeneMind Biosciences is a domestic third-generation single-molecule gene sequencing system. GeneMind Biosciences has been fighting to provide better gene sequencing solutions for clinicians and researchers. A Gene sequencer is the crown jewel in the field of gene sequencing. Entrepreneurs will lead their innovations and breakthroughs throughunremitting research and exploration. GeneMind believes that the strong pass of the difficulty is like a wall of iron, yet with firm strides, we are conquering its summit. | $38.6M | Venture - Series Unknown | Mar 10, 2025 |  |
| Panacro | Panacro is a contract research organization that provides professional medical services for clinical research in pharmaceuticals. | $14M | Series B | Dec 18, 2023 |  |
| AccuPath | AccuPath is a high-tech group dedicated to enhancing human life and health via the use of modern materials & manufacturing science and technology. |  | Venture - Series Unknown | Oct 25, 2023 |  |
| Keyto | Keyto specializes in the production of key electrical and mechanical components for microfluid system controls. | $14.9M | Series C | Jan 13, 2023 |  |
| General Biosystems | General Biosystems is a biotechnology company that focuses on high-quality, high-throughput, automated production of DNA constructs. The company through its passion in understanding how genetic information is stored and programmed in the DNA develops innovative technologies and instruments to program and physically write or print new genetic codes.The new codes will create blueprints for new or enhanced biological and biological functions. |  | Venture - Series Unknown | May 17, 2021 |  |
| ABclonal | ABclonal Technology is a rapidly growing life science research and diagnostic reagents provider. With scientists from world-class universities, the company thrives on improving the quality of life science research by providing high-quality antibodies, proteins, ELISA kits, NGS library preparation kits and molecular enzymes. | $93M | Series C | Feb 22, 2021 |  |

10 of 11 investments shown.

## Co-investors
- [Kinghall Ventures](https://shizune.co/investors/profile/kinghall-ventures) — VC Fund, 2 deals together
- [LYFE Capital](https://shizune.co/investors/profile/lyfe-capital-2) — VC Fund, 2 deals together
- [Ancheng Capital](https://shizune.co/investors/profile/ancheng-capital) — VC Fund, 1 deal together
- [C&D Emerging Investment](https://shizune.co/investors/profile/c-d-emerging-investment) — VC Fund, 1 deal together
- [Changjiang Securities](https://shizune.co/investors/profile/changjiang-securities) — VC Fund, 1 deal together
- [Co-Stone Venture Capital](https://shizune.co/investors/profile/co-stone-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does JinHe Ziben invest in?

JinHe Ziben invests primarily in Medical, Biotechnology and Genetics startups, most often at Series A and Funding Round stage. Most of the 11 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did JinHe Ziben last invest?

The most recent investment recorded for JinHe Ziben closed in May 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co